Ketamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomes.
Jennifer Jones, Joseph Redding, Emily Amador
Journal of Psychopharmacology September 25, 2026 DOI: 10.1177/02698811261488486 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open-label pilot study Peer reviewed |
|---|---|
| Sample size | 7 |
| Population | Cigarette smokers aged 29-64 with tobacco use disorder and a history of unsuccessful quit attempts |
| Interventions | Ketamine motivational enhancement therapy (MET) |
| Dose | 0.71 mg/kg |
| Duration | Three weekly sessions |
| Topics | Ketamine Neuroplasticity Esketamine |
| Keywords | Glutamate receptor antagonist Smoking cessation Tobacco use disorder |
| Key points | All seven participants completed three weekly intramuscular ketamine sessions combined with motivational enhancement therapy, and the treatment was well tolerated with no adverse events beyond expected transient psychoactive effects. Cigarette consumption and nicotine craving decreased, while withdrawal symptoms, nicotine dependence severity, and motivation to quit remained stable. The authors conclude that ketamine-enhanced psychotherapy for tobacco use disorder was feasible and call for further trials. |
Abstract
Tobacco use remains a leading preventable cause of morbidity and mortality. Although several pharmacotherapies and behavioral treatments for tobacco use disorder (TUD) exist, their overall efficacy is modest, underscoring the need for innovative treatment approaches. Ketamine, a rapid-acting glutamate receptor antagonist with neuroplasticity-enhancing properties, has shown promise in the treatment of other substance use disorders. Combining ketamine with motivational enhancement therapy (MET) may complement behavioral treatment in TUD by facilitating cognitive and psychological flexibility while strengthening individuals' ability to quit smoking. The primary aim of this open-label pilot study was to evaluate the feasibility and preliminary clinical outcomes of ketamine treatments delivered in conjunction with MET for smoking cessation in individuals with TUD. Seven cigarette smokers (ages 29-64) with a history of unsuccessful quit attempts underwent three weekly intramuscular ketamine sessions (0.71 mg/kg) combined with MET. Feasibility, the primary outcome, was assessed by study completion rates. Secondary outcomes included changes in smoking patterns, craving, nicotine dependence, withdrawal, and motivation to quit. All participants completed the interventional sessions. Ketamine sessions were well-tolerated, and no adverse events other than the expected transient psychoactive effects were observed. Cigarette consumption decreased, accompanied by reductions in nicotine craving. Withdrawal symptoms, nicotine dependence severity, and motivation to quit remained stable. Ketamine-enhanced psychotherapy for TUD was feasible and was associated with reductions in smoking and craving. These preliminary findings support further trials investigating ketamine's potential to enhance behavioral interventions for addiction.
Comparable studies
Other non-randomized and open-label trials on ketamine, most cited first.
Citations in the library
Cites 22
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Long-term follow-up of psilocybin-facilitated smoking cessation The American Journal of Drug and Alcohol Abuse July 21, 2016
- Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo Neuron July 5, 2021
- Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin Journal for the Scientific Study of Religion December 1, 2012
- Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics TIPS - Trends in Pharmacological Sciences September 24, 2021
and 17 more in the library